2019年冠状病毒病(COVID-19)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
病毒学
2019-20冠状病毒爆发
生物
医学
爆发
疾病
内科学
传染病(医学专业)
作者
Kaiyuan Sun,Jinal N. Bhiman,Stefano Tempia,Jackie Kleynhans,Vimbai Sharon Madzorera,Qiniso Mkhize,Haajira Kaldine,Meredith McMorrow,Nicole Wolter,Jocelyn Moyes,Maimuna Carrim,Neil Martinson,Kathleen Kahn,Limakatso Lebina,Jacques du Toit,Thulisa Mkhencele,Anne von Gottberg,Cécile Viboud,Penny L. Moore,Cheryl Cohen
出处
期刊:Cold Spring Harbor Laboratory - medRxiv
日期:2024-05-29
标识
DOI:10.1101/2024.05.28.24308095
摘要
Abstract Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection against symptomatic COVID-19 and severe disease. However, much less is known about the efficacy of nAbs in preventing the acquisition of infection, especially in the context of natural immunity and against SARS-CoV-2 immune-escape variants. In this study, we conducted mediation analysis to assess serum nAbs induced by prior SARS-CoV-2 infections as potential correlates of protection (CoPs) against Delta and Omicron BA.1/2 wave infections, in rural and urban household cohorts in South Africa. We find that, in the Delta wave, anti-D614G nAbs mediate 37% (95%CI 34% – 40%) of the total protection against infection conferred by prior exposure to SARS-CoV-2, and that protection decreases with waning immunity. In contrast, anti-Omicron BA.1 nAbs mediate 11% (95%CI 9 – 12%) of the total protection against Omicron BA.1/2 wave infections, due to Omicron’s neutralization escape. These findings underscore that CoPs mediated through nAbs are variant-specific, and that boosting of nAbs against circulating variants might restore or confer immune protection lost due to nAb waning and/or immune escape. However, the majority of immune protection against SARS-CoV-2 conferred by natural infection cannot be fully explained by serum nAbs alone. Measuring these and other immune markers including T-cell responses, both in the serum and in other compartments such as the nasal mucosa, may be required to comprehensively understand and predict immune protection against SARS-CoV-2.
科研通智能强力驱动
Strongly Powered by AbleSci AI